$2.20
1.35% day before yesterday
Nasdaq, Dec 24, 07:39 pm CET
ISIN
US9840152063
Symbol
XBIO

Xenetic Biosciences, Inc. Stock price

$2.20
-0.26 10.57% 1M
-0.95 30.05% 6M
-1.79 44.86% YTD
-1.95 46.99% 1Y
-0.90 29.03% 3Y
-19.70 89.95% 5Y
-1,977.80 99.89% 10Y
-591.80 99.63% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.03 1.35%
ISIN
US9840152063
Symbol
XBIO
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$4.1m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
87.0%
Return on Equity
-65.9%
ROCE
-83.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.9m | $2.6m
EBITDA
- | $-3.5m
EBIT
$-3.3m | $-3.5m
Net Income
$-3.2m | $-3.2m
Free Cash Flow
$-2.7m
Growth (TTM | estimate)
Revenue
13.5% | 2.0%
EBITDA
- | -
EBIT
24.1% | 0.9%
Net Income
22.5% | 19.2%
Free Cash Flow
7.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -136.0%
EBIT
-115.8%
Net
-110.4% | -125.7%
Free Cash Flow
-95.1%
More
EPS
$-2.1
FCF per Share
$-1.8
Short interest
0.3%
Employees
2
Rev per Employee
$1.3m
Show more

Is Xenetic Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Xenetic Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Xenetic Biosciences, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Xenetic Biosciences, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Xenetic Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2.86 2.86
13% 13%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.84 2.84
22% 22%
99%
- Research and Development Expense 3.33 3.33
3% 3%
116%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.31 -3.31
24% 24%
-116%
Net Profit -3.16 -3.16
23% 23%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Xenetic Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenetic Biosciences, Inc. Stock News

Neutral
Accesswire
15 days ago
Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting ...
Neutral
Accesswire
about one month ago
FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month extension of its collaboration with The Scripps Research Institute ("Scripps Research") and the lab of...
Neutral
Accesswire
about one month ago
Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS Newswire / November 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology techn...
More Xenetic Biosciences, Inc. News

Company Profile

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Head office United States
CEO James Parslow
Employees 2
Founded 2011
Website www.xeneticbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today